Endocrine Abstracts

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

Neuroendocrine tumors (NETs) are uncommon neoplasms with increasing incidence and limited therapeutic options, wherein identification of new diagnostic/prognostic/therapeutic biomarkers is urgently required. Alterations in somatostatin (SST)/cortistatin (CORT) and ghrelin systems have been associated to development/progression of several cancers. Thus, we evaluated expression levels of SST/CORT/ghrelin system components in gastroenteropancreatic-neuroendocrine tumors (GEP-NETs...

Pancreatic neuroendocrine tumors (PNETs) are uncommon neoplasms from the endocrine pancreas, whose incidence is recently rising. Unfortunately, an advanced stage is often found at diagnosis; thus, identification of new molecular diagnostic, prognostic, and therapeutic markers is required. Ghrelin and somatostatin/cortistatin systems are two multifunctional regulatory complexes widely distributed throughout multiple tissues, including the pancreas, where they exert diverse (pat...

Obesity (OB) and type-2 diabetes (T2D) are chronic endocrine-metabolic diseases, associated to insulin-resistance (IR), that represent capital health problems. Fortunately, both pathologies are, at least, partially reversible by dietary interventions, but the potential metabolic, molecular, cellular factors and mechanisms that might be involved in the total/partial reversion of OB/IR/T2D by dietary interventions are poorly known. Thus, in this work, we aimed evaluate the impac...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the main hepatic manifestation of obesity. MASLD was recently defined as liver steatosis in the presence of at least one cardiometabolic risk factor and reduced or absent alcohol intake. MASLD prevalence is rapidly increasing, thus becoming the fastest growing aetiology of the most common primary liver cancer, hepatocellular carcinoma (HCC), and the leading cause of liver transplantation in HCC patients. Curre...

Somatostatin is a pleiotropic neuropeptide that governs multiple biological targets, including tumor cell function, through a family of G protein-coupled receptors with 7-transmembrane domains (TMD), named sst1-5. However, we recently discovered sst5TMD4, an aberrantly spliced, truncated (only 4-TMDs) sst5-variant displaying unique molecular/functional features. sst5TM4 is overexpressed in various endocrine-related tumors exacerbating their malignant characteristics. Here, we ...

Glioblastoma (GBM) is the most prevalent and most lethal primary brain endocrine-related cancer (ERC) in adults which, in addition to the late-stage diagnosis and the lack of effective novel therapies, results in the low quality of life of patients and the poor prognosis, with a median survival from 10 to 14 months after diagnosis. Accordingly, the identification of novel molecular biomarkers of diagnosis and/or prognosis, as well as therapeutic targets becomes crucial to comb...

Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all intracranial tumors and comprise a varied type of neoplasms that, despite being rarely metastatic, can cause severe comorbidities and increased mortality related to the mass effects and hormonal hypersecretion. The high expression levels of somatostatin and dopamine receptors in these tumors has led to the use of somatostatin analogues (SSAs) and dopamine agonists (DAs) as pharmacological treatments....

Intracranial Tumors comprise a diverse group of endocrine-related tumors [ERTs; e.g. craniopharyngiomas (CPs) and pituitary-tumors (PTs)], representing significant challenges for the diagnosis/prognosis/treatment of patients, their families and health systems due to their heterogeneity, associated neurological impairment and endocrine comorbidities. However, despite recent advances, the current treatment (e.g. surgery plus irradiation in CPs, pharmacological treatment with som...

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...